Xofigo (Radium – 223) for Treatment of Prostate Cancer
Xofigo for Treatment of Metastatic CRPC with Bony Metastasis.
On May 15, 2013, the U.S. Food and Drug Administration (FDA) approved Radium-223 dichloride to treat men with symptomatic metastatic castration-resistant prostate cancer that has spread to bones but not to other organs.
Xofigo is a radiopharmaceutical has been shown to be beneficial for men with metastatic prostate cancer. Xofigo leads to decreased pain, improved quality of life, and improved survival.